Meet Cleerly Leadership and Partners
On Saturday, July 19, join Cleerly’s leadership team for an engaging conversation about our mission, clinical validation, and the future of cardiovascular care. This is a unique opportunity to connect directly with the leaders behind our innovations in a relaxed, small-group setting.
We’ll be serving heart-healthy snacks—stop by and say hello at Booth #505!
3:30PM - 4:30PM
James K. Min, MD
Founder and CEO, Cleerly
Udo Hoffmann, MD
Chief Scientific Officer, Cleerly
Jim Hartman
Chief Revenue Officer, Cleerly
Tony DeFrance, MD, FSCCT
VP of Clinical Affairs, Cleerly
Patents
Cleerly continues to revolutionize heart attack and cardiovascular disease prevention and treatment everyday by inventing world-class technology. Cleerly invests significant time and resources in research and development towards this goal. To protect Cleerly’s research and development efforts, Cleerly has vigorously developed a robust intellectual property portfolio – all part of a strategy for protecting the innovations that make Cleerly an industry leader in cardiovascular disease prevention and treatment.
Cleerly’s products and services may be covered by or for use under one or more of U.S. Patent Nos. 12,245,882, 12,144,669, 11,922,627, 11,948,301, 11,861,833, 11,967,078, 12,141,976, 11,210,786, 11,232,564, 11,276,170, 11,288,799, 11,302,001, 11,315,247, 11,367,190, 11,690,586, 11,751,826, 11,779,292, 11,832,982, 11,969,280, 12,193,862, 11,094,061, 11,094,060, 11,113,811, 11,120,550, 11,120,549, 11,132,796, 11,238,587, 11,244,451, 11,302,002, 11,308,617, 11,321,840, 11,341,644, 11,501,436, 11,660,058, 11,672,497, 11,730,437, 11,737,718, 11,751,830, 11,751,829, 11,766,230, 11,766,229, 11,896,415, 12,023,190, 12,076,175, 12,097,063, 12,156,759, 12,171,606, 12,178,627, 10,813,612, 11,317,883, 11,350,899, 11,642,092, 11,751,831, 11,759,161, and 12,138,093, as well as other patents that are pending.
For additional information, please contact legal@cleerlyhealth.com.
Solutions
About
© 2025 Cleerly, Inc.